propyphenazone
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01462370)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
- Cyclooxygenase-1INHIBITOR
PTGS1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C- Mol. weight
- 230.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL28318 ↗
Also known as
- isopropchin
- isopropylantipyrin
- isopropylantipyrine
- isopropylantipyrine
- isopropylantipyrine
- isopropylphenazone
- isopropyrine
- propifenazone
- propyfenazone
- propyphenazone
- propyphenazone
- yoshipyrin
- yoshipyrin
- yoshipyrin
- yoshipyrin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01462370 | Phase 3 | Nov 1, 2011 | Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1